Studien

Status: offen zur Rekrutierung

• DETECT V
  A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Pertuzumab in patients with HER2positive and hormone-receptor positive metastatic breast cancer.
  EudraCT Number 2014-002249-22

Status: geschlossen, Nachbeobachtungsphase

• Aphinity
  A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer
  EudraCT-Nr. 2010-022902-41
• APTneo
  Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer
  EudraCT Number 2017-000981-31
• Insema
  Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial
• Katherine
  A randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with her2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy
  EudraCT-Nr. 2012-002018-37
• Pro Pocket
  Internationale, prospektive, multizentrische Beobachtungsstudie zum "Patient Reported Outcome" bei primärer oder sekundärer Brustrekonstruktion nach Mastektomie mit einem titanisierten Polypropylen-Netz
  (TiLOOP® Bra Pocket)
• Senomac
  Survival and axillary recurrence following sentinel node- positive breast cancer without completion axillary lymph node dissection – the SENOMAC trial. A randomized study of patients with sentinel node macrometastasis.

• DETECT IV
  A multicenter single arm phase III study evaluating the efficacy of everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).
  EudraCT-Nummer 2013-001269-18
• IRENE
  Incidence and Resolution of Eribulin-induced peripheral Neuropathy bei Patienten mit local fortgeschrittenem oder metastasiertem Brustkrebs und mit max. 2 vorhergehenden chemotherapeutischen Behandlungsregimen
• RIBANNA
  Nichtinterventionelle Studie zur Beobachtung der Anwendung der zielgerichteten Therapie, endokrinen Therapie und Chemotherapie bei Patientinnen mit HR+/HER2- Mammakarzinom in der palliativen Situation ohne vorhergehende systemische Behandlung in der klinischen Routine